Towards the practical use of AI: a tool for scalable colorectal cancer screening [0.03%]
迈向实用的AI：一种结直肠癌筛查工具
E Y T Wong,A Plumb,K K Shiu
E Y T Wong
Reply to Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward [0.03%]
关于肉瘤下一代测序共识指南的回信：进展、差距及未来方向
C Serrano,J Y Blay,J V M G Bovée
C Serrano
A Multimodal Deep Learning Model for Preoperative Prediction of Postoperative Complications in Gastric Cancer [0.03%]
一种用于术前预测胃癌术后并发症的多模态深度学习模型
P A Ding,S Yang,L J Meng et al.
P A Ding et al.
Background: Clavien-Dindo (CD) grade ≥II complications occur in roughly one in five patients after curative gastrectomy for gastric cancer and independently shorten overall survival (OS) by compromising adjuvant therapy ...
Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer [0.03%]
延续故事，翻页而行：高危前列腺癌领域的预测型人工智能取代预后型指日可待
Svenja Pascale Mende,Sebastian Foersch
Svenja Pascale Mende
Measurement of Ovarian Reserve to Tailor Systemic Therapy Decisions: Future Potential or Ready for Primetime? [0.03%]
测量卵巢储备以定制全身治疗决策：未来潜力还是准备就绪？
C Valenza,A H Partridge
C Valenza
HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap [0.03%]
针对实体瘤的HER2导向TAC T细胞：向前迈出了一步，但尚未实现治疗突破
M Pedregal,V Moreno
M Pedregal
Jean-Yves Blay,David Perol
Jean-Yves Blay
Anjali Rohatgi,Ramaswamy Govindan
Anjali Rohatgi
TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer? [0.03%]
TROP2导向的抗体药物偶联物：有望成为所有晚期三阴性乳腺癌患者新的一线治疗方案吗？
A C Garrido-Castro
A C Garrido-Castro
When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology [0.03%]
论人工智能学会拒绝：肝病理诊断支持向临床责任迈进
M Svrcek,L Verlingue
M Svrcek